Literature DB >> 10698338

The covalent interaction of C3 with IgG immune complexes.

F Vivanco1, E Muñoz, L Vidarte, C Pastor.   

Abstract

Antigens (Ags) are converted into immune complexes (antigen-antibody complexes, IC) as soon as they encounter their specific antibodies (Abs). In fluids containing complement, the process of IC formation and fixation of complement components occur simultaneously. Hence, the formation of Ag-Ab-complement complexes is the normal way of eliminating Ags from a host. C3b-C3b-IgG covalent complexes are immediately formed on interaction of serum C3 with IgG-IC. These C3b-C3b dimers constitute the core for the assembly of C3/C5-convertase on the IC, which are subsequently converted into iC3b-iC3b-IgG by the complement regulators. These complexes are detected on SDS-PAGE by two bands of molecular composition, C3alpha65-C3alpha43 (band A) and C3alpha65-heavy chain of the Ab (band B), which correspond to C3b-C3b and C3b-IgG covalent interaction respectively, and that identify opsonized IC (C3b-IC). C3b can attach to Fab and Fc regions of the Ab molecule with similar efficiency. The presence of multiple C3b binding regions on IgG is considered an advantageous characteristic that facilitates the elimination of Ags in the form of C3b(n)-IC. Ab molecules on the IC recognize the Ag, and also serve as a very good acceptor for C3b binding. In this way, Ags, even if they have no acceptor sites for C3b, can be efficiently processed and removed. When C3 is activated in serum by IC or other activators, secondary C3b-IgG covalent complexes are generated, with bystander monomeric circulating IgG, and thus constitute, physiological products of complement activation. These complexes gain importance when IgG concentration is extremely high as in cases of infusion of intravenous IgG (IVIG) in several pathologies. The covalent attachment of activated complement C3 (C3b, iC3b, C3 d,g) to Ags or IC links innate and adaptative immunity by targeting Ags to different cells of the immune system (follicular dendritic cells, phagocytes, B cells). Hence C3b marks Ags definitively, from the earliest contact with the innate immune system until their complete elimination from the host.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10698338     DOI: 10.1016/s0161-5890(99)00105-4

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  6 in total

Review 1.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

2.  Immunoglobulin treatment reduces atherosclerosis in apolipoprotein E-/- low-density lipoprotein receptor-/- mice via the complement system.

Authors:  L Persson; J Borén; A Nicoletti; G K Hansson; M Pekna
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

3.  Antigen-specific airway IL-33 production depends on FcγR-mediated incorporation of the antigen by alveolar macrophages in sensitized mice.

Authors:  Takeshi Nabe; Masaya Matsuda; Tomoki Ishida; Nau Tsujimoto; Hitomi Kido; Haruna Kanaya; Hiromu Takahashi; Naoki Takemoto; Miku Nomura; Keiichi Ishihara; Satoshi Akiba; Nobuaki Mizutani
Journal:  Immunology       Date:  2018-04-19       Impact factor: 7.397

4.  Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies.

Authors:  Nirmal K Banda; Allyson K Wood; Kazue Takahashi; Brandt Levitt; Pauline M Rudd; Louise Royle; Jodie L Abrahams; Gregory L Stahl; V Michael Holers; William P Arend
Journal:  Arthritis Rheum       Date:  2008-10

5.  Biological evaluation of liposome-encapsulated hemoglobin surface-modified with a novel PEGylated nonphospholipid amphiphile.

Authors:  Vivek R Yadav; Okhil Nag; Vibhudutta Awasthi
Journal:  Artif Organs       Date:  2014-04-22       Impact factor: 3.094

6.  Serological Evidence for the Association Between Epstein-Barr Virus Infection and Sjögren's Syndrome.

Authors:  Jingxiu Xuan; Zhiqian Ji; Bin Wang; Xiaoli Zeng; Rongjuan Chen; Yan He; Peishi Rao; Puqi Wu; Guixiu Shi
Journal:  Front Immunol       Date:  2020-10-30       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.